TheraRadar
Data updated: Mar 29, 2026

ORAPRED ODT

PREDNISOLONE SODIUM PHOSPHATE
Oncology Approved 2006-06-01

Orapred ODT is a synthetic corticosteroid indicated for use as an anti-inflammatory or immunosuppressive agent in both adult and pediatric populations. It is prescribed for a wide array of conditions, including severe allergic reactions, dermatologic diseases, gastrointestinal flares (such as Crohn's disease and ulcerative colitis), and hematologic disorders. Additionally, the medication is used for the management of specific endocrine, renal, respiratory, and rheumatologic conditions, the treatment of ophthalmic and nervous system disorders (including acute exacerbations of multiple sclerosis), and the palliation of certain neoplastic conditions like leukemia and lymphoma.

Source: FDA Label • ADVANZ PHARMA

How ORAPRED ODT Works

Prednisolone is a synthetic adrenocortical steroid with potent glucocorticoid properties and slight mineralocorticoid activity. It exerts anti-inflammatory effects by inhibiting leukocyte migration, reducing capillary permeability, and suppressing the inflammatory response (including edema and fibrin deposition). As an immunosuppressant, it reduces the production of lymphocytes and eosinophils. Furthermore, it influences metabolic processes by promoting gluconeogenesis, increasing protein catabolism, and stimulating lipolysis. It also suppresses the production of endogenous corticosteroids by inhibiting the secretion of corticotropin.

1
Indication
--
Phase 3 Trials
19
Years on Market

Details

Status
Prescription
First Approved
2006-06-01
Routes
ORAL
Dosage Forms
TABLET, ORALLY DISINTEGRATING

Companies

Active Ingredient: PREDNISOLONE SODIUM PHOSPHATE

ORAPRED ODT Approval History

Loading approval history...

What ORAPRED ODT Treats

10 indications

ORAPRED ODT is approved for 10 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Allergic Conditions
  • Atopic Dermatitis
  • Drug Hypersensitivity
  • Allergic Rhinitis
  • Serum Sickness
  • Dermatitis Herpetiformis
  • Contact Dermatitis
  • Exfoliative Erythroderma
Source: FDA Label

Drugs Similar to ORAPRED ODT

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DEXAMETHASONE
DEXAMETHASONE
9 shared
ALVOGEN
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +6 more
DEXAMETHASONE INTENSOL
DEXAMETHASONE
9 shared
Hikma
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +6 more
DEXYCU KIT
DEXAMETHASONE
9 shared
EYEPOINT PHARMS
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +6 more
CELESTONE SOLUSPAN
BETAMETHASONE ACETATE
8 shared
Merck
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +5 more
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE ACETATE
7 shared
Hikma
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +4 more
DEPO-MEDROL
METHYLPREDNISOLONE ACETATE
7 shared
Pfizer
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +4 more
KENALOG-40
TRIAMCINOLONE ACETONIDE
7 shared
APOTHECON
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +4 more
PEDIAPRED
PREDNISOLONE SODIUM PHOSPHATE
7 shared
SETON PHARM
Shared indications:
Allergic RhinitisContact DermatitisAtopic Dermatitis +4 more
SOLU-CORTEF
HYDROCORTISONE SODIUM SUCCINATE
7 shared
PHARMACIA AND UPJOHN
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +4 more
SOLU-MEDROL
METHYLPREDNISOLONE SODIUM SUCCINATE
7 shared
PHARMACIA AND UPJOHN
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +4 more
METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE ACETATE
6 shared
SAGENT PHARMS INC
Shared indications:
Atopic DermatitisContact DermatitisDrug Hypersensitivity +3 more
HYDROXYZINE PAMOATE
HYDROXYZINE PAMOATE
2 shared
Novartis
Shared indications:
Atopic DermatitisContact Dermatitis
ADBRY
TRALOKINUMAB
1 shared
LEO PHARMA AS
Shared indications:
Atopic Dermatitis
ADCETRIS
BRENTUXIMAB VEDOTIN
1 shared
SEATTLE GENETICS
Shared indications:
Mycosis Fungoides
CARBINOXAMINE MALEATE
CARBINOXAMINE MALEATE
1 shared
MIKART
Shared indications:
Allergic Rhinitis
CIBINQO
ABROCITINIB
1 shared
Pfizer
Shared indications:
Atopic Dermatitis
CYCLOPHOSPHAMIDE
CYCLOPHOSPHAMIDE
1 shared
Hikma
Shared indications:
Mycosis Fungoides
CYTOXAN
CYCLOPHOSPHAMIDE
1 shared
Baxter
Shared indications:
Mycosis Fungoides
DAPSONE
DAPSONE
1 shared
SUN PHARMA CANADA
Shared indications:
Dermatitis Herpetiformis
DUPIXENT
DUPILUMAB
1 shared
Regeneron
Shared indications:
Atopic Dermatitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ORAPRED ODT FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation for the treatment of certain endocrine conditions for palliation of certain neoplastic conditions 1.1 Allergic Conditions Control of severe or incapacitating al...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.